BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• FDA

  Materialise’s 3D-Printed Maxillofacial Implants In Titanium Are First To Get Green Light For U.S. Market

  September 11, 2017

   · 

  4 min read
• Drug Development

  Boehringer Ingelheim Release: Safety And Efficacy Results From The INJOURNEY Trial Investigating OFEV (Nintedanib) With Add-On Pirfenidone Provide New Data To Support Nintedanib’s Key Role In IPF

  September 11, 2017

   · 

  5 min read
• BioMidwest

  PierianDx Release: Moffitt Cancer Center Showcases Its Blueprint For Building A Best-In-Class Precision Medicine Program At Pieriandx-Hosted Webinar

  September 11, 2017

   · 

  3 min read
• Drug Development

  Amgen And Allergan Present Phase III Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

  September 11, 2017

   · 

  15 min read
• Drug Development

  Array BioPharma Release: Phase III BEACON CRC Safety Lead-In Results In BRAF-Mutant Colorectal Cancer Presented At European Society For Medical Oncology Congress

  September 11, 2017

   · 

  12 min read
• Biotech Beach

  Ignyta Provides Update On Entrectinib And RXDX-105 At The ESMO 2017 Congress

  September 11, 2017

   · 

  8 min read
• Drug Development

  ARMO BioSciences’s Phase Ib Trials Demonstrate Continued Promising Response Rates And Survival In Patients With Advanced Pancreatic Cancer, NSCLC, And RCC

  September 11, 2017

   · 

  4 min read
• Drug Development

  Array BioPharma Release: Phase III COLUMBUS Part 2 Results In BRAF-Mutant Melanoma Presented At European Society For Medical Oncology Congress

  September 11, 2017

   · 

  12 min read
• Drug Development

  ImmusanT, Inc. Presents Data From Multiple Studies Supporting Continued Development Of Nexvax2

  September 11, 2017

   · 

  5 min read
• Drug Development

  Idera Pharma Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy

  September 11, 2017

   · 

  9 min read